Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

30 Jun 2014

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Taiho Oncology, Inc., a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), announced today detailed findings from its global Phase III RECOURSE trial of TAS-102 (nonproprietary names: trifluridine and tipiracil hydrochloride), an oral combination anticancer drug.

28 Jun 2014

Study identifies genetics as dominant risk factor in breast, prostate and colorectal cancers

A study of individuals who have been adopted has identified genetics as the dominant risk factor in 'familial' breast, prostate and colorectal cancers.

27 Jun 2014

Gene partnership may be fueling cancer spread in as much as 20% of cancers

A key cancer-causing gene, responsible for up to 20 percent of cancers, may have a weak spot in its armor, according to new research from the Masonic Cancer Center, University of Minnesota.

25 Jun 2014

Small antioxidant molecules suppress colon cancer associated with colitis

Researchers from Case Western Reserve and Dartmouth universities have shown that a class of small antioxidant molecules carries enormous promise for supressing colon cancer associated with colitis.

25 Jun 2014

Colon has safety mechanism to restrict formation and growth of adenomas

Colon cancer development starts with the formation of benign tumours called adenomas. It is estimated that between 30% and 50% of people over 50 will develop one of these tumours.

24 Jun 2014

Research roundup: Improving colon cancer screening; disparities in heart care; Medicaid expansion's effect on cities

This report estimated the effect of the Affordable Care Act (ACA) on 14 large and diverse cities: Los Angeles, Chicago, Houston, Philadelphia, Phoenix, Indianapolis, Columbus, Charlotte, Detroit, Memphis, Seattle, Denver, Atlanta, and Miami.

21 Jun 2014

UEG calls for more nurse endoscopy workforce to reduce CRC deaths

Colorectal cancer (CRC) is currently estimated to claim the lives of 214,675[1] adults in Europe, equivalent to 1 death every 3 minutes.

20 Jun 2014

Promising way to prevent disparities in colorectal cancer screening

People living in poverty are less likely to be screened regularly for colorectal cancer-and more likely to develop the disease and die from it. How to end these disparities-and raise screening rates, lower disease rates, and prevent deaths? A promising way is to mail fecal immunochemical tests (a newer kind of stool test) to populations, Beverly B. Green, MD, MPH, and Gloria D. Coronado, PhD, wrote in the June 17 JAMA Internal Medicine.

17 Jun 2014

Physicians don't always fully discuss risks and benefits of cancer screening

A national survey of patients reveals that physicians don't always fully discuss the risks and benefits of cancer screening, reports a new study in American Journal of Preventive Medicine.

13 Jun 2014

New class of tumor-targeting agents can seek out dozens of solid tumors

Scientists at the University of Wisconsin Carbone Cancer Center (UWCCC) report that a new class of tumor-targeting agents can seek out and find dozens of solid tumors, even illuminating brain cancer stem cells that resist current treatments.

13 Jun 2014

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer HealthCare has submitted an application to the European Medicines Agency (EMA) seeking marketing authorization in the European Union (EU) for EYLEA (aflibercept) Injection for the treatment of macular edema following branch retinal vein occlusion (BRVO).

11 Jun 2014

EU-funded project aims to identify potential new targets for cancer therapy

Targeted therapies have revolutionised the treatment of cancer since they were first introduced. Amongst the first medications approved in Europe, was the breast cancer drug Herceptin, which was approved in 2000. Then, the drug Glivec, was initially introduced to treat a certain form of leukaemia, and approved in 2001. Targeted therapies specifically inhibit molecules within so-called signalling pathways that usually control cell growth, death and differentiation. If they are altered, for example falsely inactivated or activated, the cells may start growing in an uncontrolled manner.

11 Jun 2014

Research roundup: Funding for safety-net hospitals; insurance competition

Safety-net hospitals rely on disproportionate-share hospital (DSH) payments to help cover uncompensated care costs and underpayments by Medicaid

9 Jun 2014

Studies confirm importance of men seeing physician on regular basis

For many men being a father is about staying strong as they protect and care for their family. Some men see going to the doctor as a weakness or nuisance, but protecting your health is one of the best things a father can do for his family.

6 Jun 2014

Study results suggest growing support for patient-centered care management

Primary care doctors practicing in a model of coordinated, team-based care that leverages health information technology are more likely to give patients recommended preventive screening and appropriate tests than physicians working in other settings, according to research published today in the Annals of Internal Medicine.

4 Jun 2014

Screening helped prevent nearly half a million colorectal cancer cases in the U.S.

An estimated half a million cancers were prevented by colorectal cancer screening in the United States from 1976 to 2009, report researchers from the Cancer Outcomes, Public Policy, and Effectiveness Research Center at Yale Cancer Center.

4 Jun 2014

Avastin and cetuximab extend life of patients with KRAS wild-type advanced bowel cancer

CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.

3 Jun 2014

Patients with advanced colorectal cancer respond well to new combination therapy

In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center found patients with advanced colorectal cancer responded well to a combination therapy of the drugs vermurafenib, cetuximab and irinotecan.

2 Jun 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

patients with KRAS wild-type MCRC can benefit from Cetuximab Or Bevacizumab With Combi Chemo Equivalent For patients with KRAS wild-type MCRC

Taiho Oncology presents TAS-102 Phase III RECOURSE trial results in mCRC patients

Study identifies genetics as dominant risk factor in breast, prostate and colorectal cancers

Gene partnership may be fueling cancer spread in as much as 20% of cancers

Small antioxidant molecules suppress colon cancer associated with colitis

Colon has safety mechanism to restrict formation and growth of adenomas

Research roundup: Improving colon cancer screening; disparities in heart care; Medicaid expansion's effect on cities

UEG calls for more nurse endoscopy workforce to reduce CRC deaths

Promising way to prevent disparities in colorectal cancer screening

Physicians don't always fully discuss risks and benefits of cancer screening

New class of tumor-targeting agents can seek out dozens of solid tumors

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

EU-funded project aims to identify potential new targets for cancer therapy

Research roundup: Funding for safety-net hospitals; insurance competition

Studies confirm importance of men seeing physician on regular basis

Study results suggest growing support for patient-centered care management

Screening helped prevent nearly half a million colorectal cancer cases in the U.S.

Avastin and cetuximab extend life of patients with KRAS wild-type advanced bowel cancer

Patients with advanced colorectal cancer respond well to new combination therapy

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Colorectal Cancer News and Research

Latest Colorectal Cancer News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in